0 (216) 358 02 38


Pazartesi-Cuma 15:30-18:30

21 Ara 2020

Renal cell carcinoma (RCC) accounts for approximately 2% of all
cancers.1 On admission, one-third of patients with RCC are at the
metastatic stage.2 Chemotherapy resistance is very high in patients
with RCC.3 Only a limited subset of patients ( 20%) benefit from
cytokine therapy.4-7 It has been shown that the median progressionfree
survival (PFS) was 4.7 months for patients with metastatic RCC
who received interferon alfa as a first-line treatment. … Read More